SE437931B - Lekemedelspreparat med antitumorverkan innehallande fosfat av polyhexametylenguanidin med angiven formel - Google Patents
Lekemedelspreparat med antitumorverkan innehallande fosfat av polyhexametylenguanidin med angiven formelInfo
- Publication number
- SE437931B SE437931B SE8400453A SE8400453A SE437931B SE 437931 B SE437931 B SE 437931B SE 8400453 A SE8400453 A SE 8400453A SE 8400453 A SE8400453 A SE 8400453A SE 437931 B SE437931 B SE 437931B
- Authority
- SE
- Sweden
- Prior art keywords
- tumor
- preparation
- polyhexamethylenguanidine
- formula
- pharmaceutical composition
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims description 7
- 229910019142 PO4 Inorganic materials 0.000 title claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title claims description 5
- 239000010452 phosphate Substances 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000001792 Sarcoma 37 Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 201000000274 Carcinosarcoma Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- -1 polyhexamethylene guanidine phosphate Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU874203066A SU1607679A3 (ru) | 1984-01-30 | 1987-08-11 | Способ борьбы с фитопатогенными грибами |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1982/000020 WO1984000105A1 (fr) | 1982-06-21 | 1982-06-21 | Preparation medicinale ayant un effet antitumoral |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8400453D0 SE8400453D0 (sv) | 1984-01-30 |
| SE8400453L SE8400453L (sv) | 1985-03-25 |
| SE437931B true SE437931B (sv) | 1985-03-25 |
Family
ID=21616776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8400453A SE437931B (sv) | 1982-06-21 | 1984-01-30 | Lekemedelspreparat med antitumorverkan innehallande fosfat av polyhexametylenguanidin med angiven formel |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59501110A (https=) |
| CA (1) | CA1194802A (https=) |
| CH (1) | CH660964A5 (https=) |
| DE (1) | DE3249514T1 (https=) |
| FR (1) | FR2535609A1 (https=) |
| GB (1) | GB2134783B (https=) |
| NL (1) | NL8220420A (https=) |
| SE (1) | SE437931B (https=) |
| WO (1) | WO1984000105A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| DE19628641C2 (de) * | 1996-07-16 | 1998-12-17 | Fresenius Ag | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
| RU2144024C1 (ru) * | 1998-10-28 | 2000-01-10 | Иркутский институт химии СО РАН | Способ получения фосфата полигексаметиленгуанидина |
| KR100557559B1 (ko) * | 1999-12-20 | 2006-03-03 | 에스케이 주식회사 | 폴리헥사메틸렌구아니딘 인산염 분말, 이의 제조방법 및이를 함유한 항균수지 |
| KR100725004B1 (ko) * | 1999-12-24 | 2007-06-04 | 에스케이 주식회사 | 살균소독제 조성물 및 이의 사용방법 |
| AT505312A1 (de) | 2007-05-15 | 2008-12-15 | Recticel Schlafkomfort Gmbh Sc | Polyurethan-werkstoff mit einer bioziden ausrüstung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3824288A (en) * | 1961-06-09 | 1974-07-16 | Hoffmann La Roche | Substituted hydrazine derivatives and process for the manufacture thereof |
| BR6457241D0 (pt) * | 1963-12-23 | 1973-06-26 | Rohm & Haas | Processo para a preparacao de t-octil-guanidinas |
| GB1492678A (en) * | 1975-08-11 | 1977-11-23 | Ici Ltd | Guanidine derivatives |
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
-
1982
- 1982-06-21 DE DE19823249514 patent/DE3249514T1/de not_active Withdrawn
- 1982-06-21 JP JP57503491A patent/JPS59501110A/ja active Pending
- 1982-06-21 CH CH90284A patent/CH660964A5/de not_active IP Right Cessation
- 1982-06-21 GB GB08403257A patent/GB2134783B/en not_active Expired
- 1982-06-21 WO PCT/SU1982/000020 patent/WO1984000105A1/ru not_active Ceased
- 1982-06-21 NL NL8220420A patent/NL8220420A/nl not_active Application Discontinuation
- 1982-10-07 CA CA000413032A patent/CA1194802A/en not_active Expired
- 1982-11-04 FR FR8218494A patent/FR2535609A1/fr active Granted
-
1984
- 1984-01-30 SE SE8400453A patent/SE437931B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2535609B1 (https=) | 1985-03-15 |
| CH660964A5 (de) | 1987-06-30 |
| SE8400453L (sv) | 1985-03-25 |
| SE8400453D0 (sv) | 1984-01-30 |
| GB2134783B (en) | 1985-10-30 |
| WO1984000105A1 (fr) | 1984-01-19 |
| NL8220420A (nl) | 1984-05-01 |
| CA1194802A (en) | 1985-10-08 |
| GB2134783A (en) | 1984-08-22 |
| JPS59501110A (ja) | 1984-06-28 |
| DE3249514T1 (de) | 1984-05-17 |
| FR2535609A1 (fr) | 1984-05-11 |
| GB8403257D0 (en) | 1984-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11219619B2 (en) | Therapeutic agent for hepatocellular carcinoma | |
| CN101812059A (zh) | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
| CN113143965A (zh) | 一种抑制肿瘤增殖的氨基富勒烯材料 | |
| JPH0558894A (ja) | 抗腫瘍剤 | |
| SE437931B (sv) | Lekemedelspreparat med antitumorverkan innehallande fosfat av polyhexametylenguanidin med angiven formel | |
| RU2084449C1 (ru) | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью | |
| CN110464722B (zh) | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 | |
| CN110917139A (zh) | 多分枝生物素修饰的乳腺癌靶向脂质体的制备和应用 | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| US7795434B2 (en) | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments | |
| CN104326937B (zh) | 抗肿瘤化合物及其医药用途 | |
| US9655875B2 (en) | Method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene | |
| US20230248717A1 (en) | N-(3-hydroxypyridine-2-carbonyl)glycine-based antitumor drug sensitizer and application thereof | |
| RU2506085C1 (ru) | Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью | |
| EP0382251A2 (en) | New adamantyl comprising tripeptides, derivatives and hydrochlorides thereof, their preparation and use | |
| CA2593202A1 (en) | Quaternary alkaloid derivatives of chelidonium majus l | |
| PT1042286E (pt) | Compostos imunomoduladores contendo grupos gama-glutamilo e beta-aspartilo e métodos para os preparar | |
| US20210132041A1 (en) | Target for drug treatment of tumor metastasis and use thereof | |
| CA1326487C (en) | Mitomycin analogs | |
| Fisher et al. | Stimulatory effect of amphotericin B methyl ester on the growth of LM and Vero cells | |
| SU1200851A3 (ru) | Способ получени димера Винка или его фармацевтически приемлемых солей | |
| CN119019463B (zh) | 一种具有西替利嗪四价铂结构的衍生物及其制备方法和用途 | |
| CN111110685A (zh) | 一种含伊布替尼的药物组合物及其应用 | |
| JPS59222417A (ja) | Ｎ，Ｎ−ジエチル−５−メチル−２Ｈ−１−ベンゾチオピラノ−〔４，３，２−ｃｄ〕−インダゾ−ル−２−エタナミン組成物 | |
| US20170246138A1 (en) | Method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8400453-0 Effective date: 19880318 Format of ref document f/p: F |